| Dysregulated mi RNA biogenesis downstream of cellular stress and ALS‐causing mutations: a new mechanism for ALS A Emde, C Eitan, LL Liou, RT Libby, N Rivkin, I Magen, I Reichenstein, ... The EMBO journal 34 (21), 2633-2651, 2015 | 200 | 2015 |
| Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer H Liu, C Zang, A Emde, MD Planas-Silva, M Rosche, A Kühnl, CO Schulz, ... European journal of pharmacology 591 (1-3), 43-51, 2008 | 157 | 2008 |
| mi RNA s at the interface of cellular stress and disease A Emde, E Hornstein The EMBO journal 33 (13), 1428-1437, 2014 | 127 | 2014 |
| Immunoprofiles of 11 biomarkers using tissue microarrays identify prognostic subgroups in colorectal cancer T Knösel, A Emde, K Schlüns, Y Chen, K Jürchott, M Krause, M Dietel, ... Neoplasia 7 (8), 741-747, 2005 | 104 | 2005 |
| Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer A Emde, WJ Köstler, Y Yarden Critical reviews in oncology/hematology 84, e49-e57, 2012 | 54 | 2012 |
| Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions CR Pradeep, A Zeisel, WJ Köstler, M Lauriola, J Jacob-Hirsch, ... Oncogene 31 (31), 3569-3583, 2012 | 44 | 2012 |
| Simultaneous inhibition of estrogen receptor and the HER2 pathway in breast cancer: effects of HER2 abundance A Emde, G Mahlknecht, K Maslak, B Ribba, M Sela, K Possinger, ... Translational oncology 4 (5), 293-300, 2011 | 36 | 2011 |
| Combining epitope-distinct antibodies to HER2: cooperative inhibitory effects on invasive growth A Emde, CR Pradeep, DA Ferraro, N Ben-Chetrit, M Sela, B Ribba, Z Kam, ... Oncogene 30 (14), 1631-1642, 2011 | 26 | 2011 |
| Modeling and predicting optimal treatment scheduling between the antiangiogenic drug sunitinib and irinotecan in preclinical settings S Wilson, M Tod, A Ouerdani, A Emde, Y Yarden, A Adda Berkane, ... CPT: pharmacometrics & systems pharmacology 4 (12), 720-727, 2015 | 19 | 2015 |
| Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME). Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer A Emde, WJ Köstler, Y Yarden Crit Rev Oncol Hematol 84 (Suppl 1), e49-e57, 2012 | 16 | 2012 |
| Combination of fulvestrant and lapatinib in non-HER2-overexpressing and adriamycin-resistant breast cancer cell lines AM Emde, K Maslak, H Liu, AE Reles, K Possinger, J Eucker Journal of Clinical Oncology 25 (18_suppl), 14050-14050, 2007 | 5 | 2007 |
| Therapie des Mammakarzinoms J Eucker, A Emde, K Possinger Der Internist 12 (47), 1223-1228, 2006 | 4 | 2006 |
| DOWNREGULATION OF miR-218 MAY BE USED AS A BIOMARKER FOR HUMAN ALS E Hornstein, A Chen, I Reichenstein, AM Emde US Patent App. 14/671,848, 2015 | 3 | 2015 |
| Methods of diagnosing and treating motor neuron diseases and other cellular stress-related diseases E Hornstein, AM Emde US Patent 10,159,670, 2018 | 1 | 2018 |
| Dysregulated miRNA biogenesis downstream of cellular stress and ALS-causing mutations: A new mechanism for ALS AM Emde PQDT-Global, 2016 | 1 | 2016 |
| Honokiol (from magnolia) H Liu, C Zang, A Emde, MD Planas-Silva, M Rosche, A Kühnl, CO Schulz, ... Eur J Pharmacol 591 (1-3), 43-51, 2008 | 1 | 2008 |
| Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions CR Pradeep, A Zeisel, WJ Köstler, M Lauriola, J Jacob-Hirsch, ... Oncogene, 1-1, 2024 | | 2024 |
| Quantification of Dicer Activity in Mammalian Cell Lysates Using a Non-radioactive Fluorescence Method A Emde, N Rivkin, MA Behlke, E Hornstein MicroRNA Technologies, 21-27, 2017 | | 2017 |
| Thesis for the degree AM Emde | | 2016 |
| Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer. LHY Liu HongYu, CB Zang, A Emde, MD Planas-Silva, M Rosche, ... | | 2008 |
Christos SotiriouUniversité Libre de BruxellesVerified email at bordet.be
